PMID- 19766624
OWN - NLM
STAT- MEDLINE
DCOM- 20100217
LR  - 20131121
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 622
IP  - 1-3
DP  - 2009 Nov 10
TI  - PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid 
      accumulation and inflammation in LDLR-/- mice.
PG  - 45-51
LID - 10.1016/j.ejphar.2009.09.002 [doi]
AB  - Although peroxisome proliferator-activated receptor delta (PPARdelta) has been 
      implicated in energy metabolism and lipid oxidation process, detailed roles of 
      PPARdelta in lipid homeostasis under pathologic conditions still remain 
      controversial. Thus, we investigated the effect of PPARdelta ligand L-165041 on 
      Western diet-induced fatty liver using low-density lipoprotein receptor-deficient 
      (LDLR(-/-)) mice. LDLR(-/-) mice received either L-165041 (5mg/kg/day) or vehicle 
      (0.1N NaOH) with Western diet for 16 weeks. According to our data, L-165041 
      drastically reduced lipid accumulation in the liver, decreasing total hepatic 
      cholesterol and triglyceride content compared to the vehicle group. Gene 
      expression analysis demonstrated that L-165041 lowered hepatic expression of 
      PPARgamma, apolipoprotein B, interleukin 1 beta (IL-1beta), and interleukin-6. In 
      contrast, L-165041 increased hepatic expressions of PPARdelta, lipoprotein lipase 
      (LPL), and ATP-binding cassette transporter G1 (ABCG1). Our data suggest that 
      L-165041 might be effective in preventing Western diet-induced hepatic steatosis 
      by regulating genes involved in lipid metabolism and the inflammatory response.
FAU - Lim, Hyun-Joung
AU  - Lim HJ
AD  - Division of Cardiovascular and Rare Diseases, Center for Biomedical Sciences, 
      National Institute of Health, Republic of Korea.
FAU - Park, Jin-Hee
AU  - Park JH
FAU - Lee, Seahyoung
AU  - Lee S
FAU - Choi, Hye-Eun
AU  - Choi HE
FAU - Lee, Kuy-Sook
AU  - Lee KS
FAU - Park, Hyun-Young
AU  - Park HY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090918
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Cytokines)
RN  - 0 (Ligands)
RN  - 0 (PPAR delta)
RN  - 0 (Phenoxyacetates)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, LDL)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Animals
MH  - Apolipoproteins B/genetics
MH  - Cholesterol/metabolism
MH  - Cytokines/genetics
MH  - Diet/*adverse effects
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - Inflammation/chemically induced/*metabolism
MH  - Ligands
MH  - Lipid Metabolism/*drug effects
MH  - Liver/*drug effects/metabolism
MH  - Mice
MH  - PPAR delta/genetics/*metabolism
MH  - Phenoxyacetates/metabolism/*pharmacology
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptors, LDL/*deficiency/genetics
MH  - Triglycerides/metabolism
EDAT- 2009/09/22 06:00
MHDA- 2010/02/18 06:00
CRDT- 2009/09/22 06:00
PHST- 2009/03/19 00:00 [received]
PHST- 2009/07/26 00:00 [revised]
PHST- 2009/09/08 00:00 [accepted]
PHST- 2009/09/22 06:00 [entrez]
PHST- 2009/09/22 06:00 [pubmed]
PHST- 2010/02/18 06:00 [medline]
AID - S0014-2999(09)00768-7 [pii]
AID - 10.1016/j.ejphar.2009.09.002 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2009 Nov 10;622(1-3):45-51. doi: 10.1016/j.ejphar.2009.09.002. 
      Epub 2009 Sep 18.